Next Article in Journal
Application of Live-Cell RNA Imaging Techniques to the Study of Retroviral RNA Trafficking
Next Article in Special Issue
Renal Alterations in Feline Immunodeficiency Virus (FIV)-Infected Cats: A Natural Model of Lentivirus-Induced Renal Disease Changes
Previous Article in Journal
Analysis of Sequence Polymorphism and Population Structure of Tomato chlorotic dwarf viroid and Potato spindle tuber viroid in Viroid-Infected Tomato Plants
Previous Article in Special Issue
Evaluation of Different Antiretroviral Drug Protocols on Naturally Infected Feline Immunodeficiency Virus (FIV) Cats in the late Phase of the Asymptomatic Stage of Infection
Viruses 2012, 4(6), 954-962; doi:10.3390/v4060954
Article

Administration of Fozivudine Tidoxil as a Single-Agent Therapeutic during Acute Feline Immunodeficiency Virus Infection Does Not Alter Chronic Infection

 and *
Received: 12 April 2012; in revised form: 19 May 2012 / Accepted: 5 June 2012 / Published: 7 June 2012
(This article belongs to the Special Issue Feline Retroviruses)
View Full-Text   |   Download PDF [215 KB, uploaded 7 June 2012]   |   Browse Figures
Abstract: Initiating combination antiretroviral therapy (ART) during acute HIV infection has been correlated with decreased viral set point and improved lymphocyte function. However, the long term effects of single-agent therapy administered only during the acute stage of infection (interrupted treatment) remain largely uncharacterized. In this study we provide longitudinal data using the feline immunodeficiency virus (FIV) model for HIV infection. Infected cats were treated with a prophylactic single-agent therapy, Fozivudine tidoxil (FZD), for six weeks, starting one day before infection. The initial acute infection study, reported elsewhere, demonstrated a decrease in plasma- and cell-associated viremia at two weeks post-infection (PI) in FZD-treated cats as compared to placebo-treated cats. We hypothesized that this early alteration in plasma- and cell-associated viremia would alter the virus set point and ultimately affect the outcome of chronic infection. Here we provide data at one, two and three years PI for plasma- and/or cell-associated viremia, total lymphocyte counts and CD4:CD8 ratios. There was no difference in viremia or cell counts between treated and nontreated groups at all time points tested. Contrary to our hypothesis, these results suggest that treatment with a single agent anti-retroviral drug during acute lentivirus infection does not significantly alter viral load and immune function during the chronic, asymptomatic stage of infection.
Keywords: acquired immunodeficiency syndrome; lentivirus; FIV; antiretroviral therapy (ART); Zidovudine; Fozivudine acquired immunodeficiency syndrome; lentivirus; FIV; antiretroviral therapy (ART); Zidovudine; Fozivudine
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Miller, M.M.; Fogle, J.E. Administration of Fozivudine Tidoxil as a Single-Agent Therapeutic during Acute Feline Immunodeficiency Virus Infection Does Not Alter Chronic Infection. Viruses 2012, 4, 954-962.

AMA Style

Miller MM, Fogle JE. Administration of Fozivudine Tidoxil as a Single-Agent Therapeutic during Acute Feline Immunodeficiency Virus Infection Does Not Alter Chronic Infection. Viruses. 2012; 4(6):954-962.

Chicago/Turabian Style

Miller, Michelle M.; Fogle, Jonathan E. 2012. "Administration of Fozivudine Tidoxil as a Single-Agent Therapeutic during Acute Feline Immunodeficiency Virus Infection Does Not Alter Chronic Infection." Viruses 4, no. 6: 954-962.


Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert